Welcome to CREANT!

CREANT is the acronym of the Center for Radiopharmaceuticals Antwerp.

What we do

We create innovative radiopharmaceutical solutions that will improve the lives of cancer patients around the globe.

Our mission

CREANT’s mission is to ensure that the right cancer treatment is given to the right patient at the right time. By developing radiopharmaceuticals that target specific cancer markers we aim to provide an individually tailored therapeutic intervention.

Creating innovative radiopharmaceuticals for tomorrow’s theranostics.


European Molecular Imaging Meeting (EMIM) 2023 Award

Louis Lauwerys a PhD student from CREANT has won a poster award at the European Molecular Imaging Meeting (EMIM) in Salzburg (Austria) for his work on the design and evaluation of a novel caspase-3 radiotracer for monitoring apoptosis in response to cancer therapy. Congratulations Louis!


PhD defence Jonatan Dewulf

On November 3, 2022, Jonatan Dewulf, a member of CREANT, has defended his PhD thesis entitled: ‘Elucidating the tumor microenvironment: immuno-PET imaging of RANKL and CD70’ Congratulations Jonatan!



Our team has developed a novel immuno-PET imaging tool that can help tailoring cancer therapies. Check out our latest publication.


Our partners

University of Antwerp
Molecular Imaging Center Antwerp (MICA)
Antwerp University Hospital (UZA)